A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP-196) in Subjects with Previously Untreated Mantle Cell Lymphoma

IRB/UVA Tracking #
19861
Contact
Erica Stallard
Contact Email
Contact Phone
Phase
III
Primary purpose
Treatment
Cancer PI
Craig Portell
Status
OPEN TO ACCRUAL
Ages
Adult